Summary: Researchers have developed a small-molecule drug that shows promise as a new approach to treating multiple sclerosis (MS). Unlike current therapies that primarily target the immune system, this experimental compound acts on the brain’s glutamate signaling pathways and, in preclinical studies, both reduced MS-like symptoms and promoted repair of damaged myelin.
The treatment demonstrated beneficial effects in two different animal models of MS, marking an important advance toward clinical testing and offering renewed hope for improved therapies that address neuroprotection and myelin repair in addition to immune modulation.
Key Facts:
- The candidate drug targets the glutamate system—specifically AMPA receptor–mediated excitotoxicity—representing a novel mechanism for MS therapy compared with standard immune-targeting drugs.
- In preclinical models the compound reduced neurological deficits and supported restoration of myelin and motor function, addressing core clinical challenges in MS care.
- Researchers at CAMH and the University of Aberdeen are advancing the program toward human trials, supported by preclinical data, patents, and funding from MS research organizations.
Source: CAMH
CAMH-led preclinical research has produced a small-molecule candidate that may become a novel treatment option for multiple sclerosis.
The study was published in the journal Science Advances and builds on earlier work by Dr. Fang Liu, who identified a new drug target for MS. The research team synthesized and tested a lead compound that proved effective in two complementary animal models, moving this line of investigation closer to potential clinical application.
Multiple sclerosis is a progressive neurological disorder without a cure, characterized by a range of disabling symptoms such as coordination and balance problems, cognitive impairment, muscle weakness, and mood disturbances. MS commonly involves damage to myelin, the insulating layer around nerve fibers in the brain and spinal cord, and most approved treatments so far focus on modulating the immune system to limit inflammatory damage.
Dr. Fang Liu and colleagues adopted a different strategy: targeting glutamate-driven excitotoxicity. The newly developed compound selectively modulates AMPA receptor activity at an allosteric site, aiming to prevent pathological overactivation without disrupting essential neurotransmission. In experimental autoimmune encephalomyelitis and cuprizone models, the compound improved neurological function, promoted remyelination, and reduced inflammatory responses—while preserving baseline synaptic activity and learning and memory in the animals tested.
“Our compound had a striking effect on rescuing myelin and motor function in laboratory models,” said Dr. Liu, emphasizing the potential to complement existing MS treatments and expand therapeutic options for patients.
Dr. Iain Greig, a medicinal chemistry expert at the University of Aberdeen, and his team are optimizing the molecules identified by Dr. Liu into more advanced, drug-like candidates suitable for further development. He commented that the discovery represents an unusually strong starting point for drug development and expressed commitment to advancing the program toward clinical trials.
Funding for this research has come largely from the Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society (USA) through its Fast Forward commercial research program. Representatives from these organizations noted their support for the early-stage development of a neuroprotective strategy that could complement immune-targeted therapies.
Dr. Liu and collaborators believe the efficacy and tolerability evidence generated in these preclinical studies make the compound a promising candidate for eventual human testing. Next steps include additional preclinical investigations focused on safety, pharmacokinetics, and chemical stability. Patent applications have been filed to protect the intellectual property, and the teams are actively seeking industry partners to support progression to clinical trials over the coming years.
About this neuropharmacology and multiple sclerosis research news
Author: Hayley Clark
Source: CAMH
Contact: Hayley Clark – CAMH
Image credit: Neuroscience News
Original Research: Open access. “Small-molecule targeting AMPA-mediated excitotoxicity has therapeutic effects in mouse models for multiple sclerosis” by Fang Liu et al., published in Science Advances.
Abstract
Small-molecule targeting AMPA-mediated excitotoxicity has therapeutic effects in mouse models for multiple sclerosis
While most MS research and therapies target autoimmune mechanisms that drive demyelination, emerging evidence suggests neurodegeneration and excitotoxic mechanisms may precede or exacerbate immune-mediated damage. Glutamate receptor antagonists have shown potential in animal studies but can impair normal neuronal function if they broadly block glutamate signaling.
This study describes discovery of a small molecule that prevents AMPA-mediated excitotoxicity by binding an allosteric site on the GluA2 subunit. Using machine learning–guided screening, researchers identified a lead compound that restores neurological function and promotes remyelination while dampening immune responses in experimental autoimmune encephalomyelitis and cuprizone models. Importantly, the compound did not compromise baseline neurotransmission or cognitive performance in preclinical testing.
These findings support development of a new class of MS therapeutics that act through a mechanism distinct from current immune-modulating drugs, offering potential as either an alternative or a complementary treatment to existing therapies.